Novavax (NVAX) Misses Q4 EPS by 99c ; Offers Guidance

Novavax (NASDAQ: NVAX) reported Q4 EPS of ($1.44), $0.99 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $291 million versus the consensus estimate of $321.97 million.

GUIDANCE:

Novavax sees FY2024 revenue of $0.8-1 billion, versus the consensus of $0.97 billion.

For earnings history and earnings-related data on Novavax (NVAX) click here.

You May Also Be Interested In

• BofA raises AMD target to $720, sees server CPU TAM tripling to $211B by 2030
• KLX Energy narrows Q3 2026 revenue guidance, completes rights offering
• Moody’s upgrades Cushman & Wakefield rating to Ba3 on debt reduction